


60[™] ANNUAL REPORT 2019 - 2020

FIGHTING AT THE FOREFRONT.



WE ARE DOING OUR BIT. YOU CAN HELP TOO. STAY SAFE

FINANCIAL SUMMARY 10 Years' Performance

CAPITAL ACCOUNT

₹ In lakhs

	2010-11	2011-12	2012-13	2013-14	2014-15	2015-16	2016-17	2017-18	2018-19	2019-20
Share Capital	418	418	418	418	418	1,253	1,253	1,253	1,253	1,253
Reserves	5,716	6,503	7,145	8,171	9,672	10,958	12,802	13,709	15,207	14,968
Borrowings	696	702	52	-	-	211	-	244	439	4,456
Gross Block	1,786	1,936	2,294	2,387	2,295	3,361	3,364	2,640	6,036	9,510
Net Block	1,028	1,095	1,308	1,233	982	1,850	1,759	2,262	5,502	8,404

REVENUE ACCOUNT

	2010-11	2011-12	2012-13	2013-14	2014-15	2015-16	2016-17	2017-18	2018-19	2019-20
Total Revenue	17,903	22,908	24,490	27,055	28,874	32,973	22,454	24,863	32,537	31,117
Profit before Depreciation & Tax	1,861	1,937	1,935	2,722	3,513	4,020	2,955	2,525	3,406	2,619
Profit before Tax	1,751	1,805	1,768	2,548	3,186	3,794	2,759	2,342	3,240	1,916
Profit After Tax	1,229	1,285	1,253	1,759	2,199	2,580	2,005	1,651	2,337	1,431
Earnings Per Share (₹)	14.71	15.38	15.01	21.06	26.00	10.30	8.00	6.59	9.33	5.71
Dividend Per Share (₹)	5.00	5.50	6.00	7.75	7.00	2.50	2.50	2.75	2.75	2.75

Notes :

- 1) EPS & DPS reported w.e.f. FY 2015-16 is after giving effect to Bonus Issue of Shares in the ratio of 2:1 i.e. 2 Bonus Shares for each Equity Share held.
- 2) Figures for the FY 2016-17 and onwards are reported as per Ind AS requirements.



CONTENTS

Corporate Information	2
MD's Message to the Shareholders	3
List of Board of Directors	4
List of Senior Management and Key Managerial Personnel	6
Notice	7
Directors' Report	17
Management Discussion and Analysis	43
Corporate Governance Report	46
Certificate on Corporate Governance	62
Independent Auditor's Report	64
Balance Sheet as on March 31, 2020	72
Statement of Profit and Loss for the year ended on March 31, 2020	73
Cash Flow Statement	74
Notes to Financial Statements	77



ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586

Sixtieth Annual Report of the Board of Directors with the Audited Statement of Accounts for the year ended March 31, 2020

Board of Directors	: Mr. Jasvantlal Shah Mr. Bipin Shah Mr. Lalitkumar Shah Mr. Bharat Shah Mr. Arun Todarwal Mr. Sandeep Joshi (Appointed w.e.f. 22/08/2019) Mr. Harmanbhai Patel Dr. (Ms.) Mita Dixit Mr. Samir Shah Mr. Ketan Shah Mr. Ritesh Shah Mr. Vivek Shah	Chairman - Independent Director Managing Director Director Director Independent Director Independent Director Independent Director Director Director Whole Time Director & CEO Whole Time Director & CEO (R&D)	(DIN: 00372600) (DIN: 00083244) (DIN: 00396345) (DIN: 00083354) (DIN: 00020916) (DIN: 00516409) (DIN: 07342390) (DIN: 07342390) (DIN: 08198165) (DIN: 00157396) (DIN: 00083326) (DIN: 02496729) (DIN: 02878724)
Chief Financial Officer	: Mr. Darshan Rampariya		
Company Secretary & Compliance Officer	: Ms. Ashwini Ambrale		
Auditors	: M/s. Jayantilal Thakkar & Co. Chartered Accountants, (Firm Registration No. 104133W)		
Bankers	: HDFC Bank Ltd.		
Registrars and Transfer Agents	: Bigshare Services Private Limited 1 st Floor, Bharat Tin Works Buildin Opp. Vasant Oasis Makwana Roa Marol, Andheri East, Mumbai 4000 Tel: +91-22-6263 8200 Fax: +91-22-6263 8299 Email: investor@bigshareonline.com	g, d, 059	
Registered Office	: 3-A, Shivsagar Estate, North Wing Dr. Annie Besant Road, Worli, Mumbai - 400018 Tel : +91-22-6622 7575 Fax: +91-22-6622 7600 Email: anuh@sk1932.com Web: www.anuhpharma.com),	
Factory	: E-17/3, 17/4 & E-18 MIDC, Tarapur, Boisar, Dist. Palgh Tel : +91-7410055574/75	ar - 401506	
R & D Division	: A-514, TTC Industrial Area, MIDC, Mahape, Navi Mumbai - 40 Tel : +91-22-4119 3333 Fax: +91-22-4119 3300 Email: research@anuhpharma.com Web: www.aplrnd.com		



Managing Director's Message to the Shareholders



Mr. Bipin N. Shah Managing Director

Dear Shareholders,

One of the great privileges of working in Pharmaceutical industry is the opportunity to directly contribute towards the advancement quality of life. This has always been our greatest source of purpose in propelling Anuh Pharma forward. Today, as the world faces an unprecedented pandemic we continue playing our part in serving humanity.

It gives me great pleasure to present to you our Company's 60th Annual report, in a nutshell.

Our Operational Revenue for the Financial year 2019-20 amounted to ₹ 30,695 Lakhs as against ₹ 32,066 Lakhs for the previous year, a decrease of 4.27 %.

Our PBT has gone down from ₹ 3240 lakhs to ₹ 1,916 lakhs for this year. The main reasons for the decrease in revenue & PBT are as follows:

- I. Export restrictions imposed by Indian Government on majority of the products for February and March 2020. This step was taken by Government to avoid shortages in India.
- II. We had to write off huge depreciation due to commissioning of our expansion project.

EXPANSION PROJECT:

We are pleased to inform you that our "NEW EXPANSION PROJECT" is fully operational and due to this increased capacity, we hope to achieve at least 30% additional revenue in 2020-2021.

Moreover, we have started validation batches for: 1. Telmisartan 2. Glyclazide 3. Moxifloxacin 4. INH and we propose to start commercial production during 2nd half of 2020-2021.

We continue to allocate total resources towards building the API & Bulk Drug Segment. Our state-of-the-art R&D Facility at Navi Mumbai works relentlessly on the development of newer and better pharmaceutical raw material.

An advance stage works is going on for the following products:

- 1. Aripiprazole
- 2. Olanzapine
- 3. Fexofenadine
- 4. Sitagliptin
- 5. Celecoxib

COVID 19 CRISIS :

Even during COVID 19 crisis, we were successful in running our plant continuously, being an essential drug company.

We are fully complying to requisite safety norms like social distancing, sanitising, temperature monitoring, masking etc.

To ensure presence of maximum staff & workers, we have provided "pick up & drop facility" and also incentivised the employees.

GLOBAL cGMP COMPLIANCE :

During 2019-2020, we were inspected by USFDA authorities, and we are pleased to inform that we have successfully cleared the USFDA inspection without any observations by the US authorities.

Adherence to the stringent cGMP requirements of global regulators is a non-compromising objective for us. Compliance to these standards has become a key determinant of future success for the API industry. We continue to invest significant time & resources in ensuring that we remain committed to 24/7 cGMP compliance. Over the past years our cGMP capabilities have increased significantly. We recognise this as a pertinent area, and are targeting appropriate technology based solutions to facilitate cGMP compliance with an increased focus on requisite manpower training.

TRANSFORMATION:

In order to generate long term sustainable value for Shareholders, businesses need to continuously involve & transform themselves to build a strong foundation for future growth. At Anuh Pharma we have decided on a transformational journey to make Anuh Pharma a Company that is in tune with the times.

With Warm Regards,

Mr. Bipin N. Shah

Manging Director Anuh Pharma Ltd.



Board of Directors



Mr. Jasvantlal G. Shah Chairman



Mr. Bipin N. Shah Managing Director



Mr. Lalitkumar P. Shah Director



Mr. Arun L. Todarwal Director



Mr. Bharat N. Shah Director



Dr. (Ms.) Mita C. Dixit Director



Board of Directors



Mr. Harmanbhai T. Patel Director



Mr. Sandeep M. Joshi Director



Mr. Ketan L. Shah Director



Director

Mr. Ritesh B. Shah Whole Time Director & CEO



Mr. Vivek B. Shah Whole Time Director & CEO (R&D)



Senior Management & Key Managerial Personnel



Mr. Rajendrakumar C. Kotadia Vice President - Marketing



Dr. Uday V. Korgaonkar Head of the Department - R & D



Mr. Surendra U. Rai Assistant General Manager - QC



Mr. Kaushal H. Shroff Senior Marketing Executive



Mr. Bhavesh Mudaliar Assistant General Manager - Production



Dr. Rajiv P. Sutar Vice President - Technical



Dr. Sushil J. Dheer General Manager - R & D



Mr. Ketan N. Shah Senior Marketing Executive



Mr. Nilesh S. Mohare Assistant General Manager - QA



Mr. Babu Moghaveera Assistant General Manager - Technical



Mr. Darshan D. Rampariya Chief Financial Officer



Mr. Tejas S. Patel General Manager- QA



Mr. Gaurav S. Shah Head Anti Malarials



Ms. Ashwini S. Ambrale Company Secretary & Compliance Officer



Mr. Monil R. Shah Marketing & Business Development Executive

NOTICE

SIXTIETH ANNUAL GENERAL MEETING of the Members of ANUH PHARMA LIMITED will be held on Friday, 11th September, 2020 at 12.00 Noon through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") to transact the following business:

ORDINARY BUSINESS:

- 1. To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2020, including Audited Balance Sheet as at March 31, 2020 and the Statement of Profit & Loss for the year ended on that date together with the Reports of the Board of Directors and Auditors thereon for the said year.
- 2. To confirm the interim dividend paid for the financial year 2019-20.
- 3. To appoint a Director in place of Mr. Bharat N. Shah (DIN: 00083354) who retires by rotation and, being eligible offers himself for re-appointment.
- 4. To appoint a Director in place of Mr. Samir J. Shah (DIN: 00157396) who retires by rotation and, being eligible offers himself for re-appointment.

SPECIAL BUSINESS :

5. To consider and, if thought fit, to pass, with or without modification(s), the following resolution as an **Ordinary Resolution**:

"**RESOLVED THAT** pursuant to the provisions of Section 148 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or reenactment(s) thereof, for the time being in force), the remuneration of ₹ 1,10,000/- plus applicable tax and reimbursement of the out of pocket expenses, if any, payable to Mr. Ankit Kishor Chande, Cost Accountant, (Certificate of Practice No. 34051) being a Cost Auditor, to conduct the audit of the Cost Accounting records related to Bulk Drugs of the Company for the financial year 2020-21, be and is hereby ratified.

RESOLVED FURTHER THAT Mr. Bipin N. Shah, Managing Director (DIN: 00083244), Mr. Bharat N. Shah (DIN: 00083354), Mr. Lalitkumar P. Shah, (DIN: 00396345) Directors or the Company Secretary of the Company be and is hereby severally authorized to take all such necessary steps and actions and authorized to do all the necessary formalities and to sign and submit the necessary papers and forms with required authorities including E-Form with Registrar of Companies to give effect to this resolution."

6. To consider and if thought fit, to pass, with or without modification(s), the following resolution as a Ordinary Resolution:

"**RESOLVED THAT** pursuant to the provisions of Section 63 and other applicable provisions of the Companies Act, 2013 read with the Rules relating thereto, the relevant clauses of the Memorandum of Association & Articles of Association of the Company and the recommendation of the Board of Directors of the Company and subject to the guidelines issued by the Securities and Exchange Board of India (SEBI), including the provision of the SEBI (Issue of Share Capital and Disclosure Requirements) Regulations, 2018 (as amended from time to time) the approval of Members be and is hereby granted to capitalize a sum of ₹ 12,52,80,000/- (Rupees Twelve Crores Fifty Two Lakhs Eighty Thousand only) out of the reserves set free for distribution amongst the equity shareholders by issue of 2,50,56,000 bonus shares of ₹ 5/- (Rupees Five Only) each credited as fully paid to the equity shareholders in the proportion of 1 (One) equity share for every 1 (One) equity share held by them as on the record date i.e. Monday, September 21, 2020.

RESOLVED FURTHER THAT the bonus shares to be issued as fully paid equity shares shall be subject to the Memorandum and Articles of Association of the Company ranking in all respects pari passu to the existing equity shares.

RESOLVED FURTHER THAT Mr. Bipin N. Shah, Managing Director (DIN: 00083244), Mr. Bharat N. Shah (DIN: 00083354), Mr. Lalitkumar P. Shah, (DIN: 00396345) Directors or the Company Secretary of the Company be and is hereby severally authorized to take all such necessary steps and actions and authorized to do all the necessary formalities and to sign and submit the necessary papers and forms with required authorities including E-Form with Registrar of Companies to give effect to this resolution."



7. To consider and if thought fit, to pass, with or without modification(s), the following resolution as a **Special Resolution**:

"**RESOLVED THAT** pursuant to applicable provisions of the Companies Act, 2013 and rules made thereunder including any statutory modification(s) or re-enactment thereof, Regulation 17(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in accordance with the provisions of SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018, approval of the Members be and hereby accorded to Mr. Bharat N. Shah (DIN: 00083354), Non-Executive Director of the Company, who will attain the age of 75 years in the month of September, 2021 to continue as a Director of the Company on completion of such age.

RESOLVED FURTHER THAT Mr. Bipin N. Shah, Managing Director, (DIN: 00083244), Mr. Lalitkumar P. Shah (DIN: 00396345), Director or the Company Secretary of the Company be and is hereby severally authorized to take all such necessary steps and actions and authorized to do all the necessary formalities and to sign and submit the necessary papers and forms with required authorities including E-Form with Registrar of Companies to give effect to this resolution."

For and on behalf of the Board of Directors

Sd/-Ashwini Ambrale Company Secretary & Compliance Officer (M. No.: A32456)

Registered Office:

CIN: L24230MH1960PLC011586 3-A, Shiv Sagar Estate, North Wing, Dr. Annie Besant Road, Worli, Mumbai - 400 018 Tel: +91-22 6622 7575; Fax: +91-22 6622 7600 Email: anuh@sk1932.com; Web: www.anuhpharma.com;

Place : Mumbai Date : August 07, 2020

NOTES:

- 1. The Register of Members and Share Transfer Book of the Company shall remain closed on **Friday**, **September 11**, **2020** for the purpose of Bonus Issue of Equity Shares and 59th Annual General Meeting of the Company.
- 2. In view of the continuing COVID-19 pandemic and restrictions imposed on the movement of people, the Ministry of Corporate Affairs (MCA) vide its Circular dated May 05 2020 read with Circulars dated April 08, 2020 and April 13, 2020 (collectively referred to as MCA Circulars) and Securities and Exchange Board of India (SEBI) vide its Circular No. SEBI/ HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020 have permitted the holding of the Annual General Meeting (AGM) through Video Conference/ Other Audio Visual Means, without the physical presence of the Members at a common venue.
- 3. The venue of the AGM shall be deemed to be the registered office of the Company at 3A, Shivsagar Estate, North Wing, Dr. Annie Besant Road, Worli, Mumbai 400018.
- 4. Pursuant to the provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the Circulars issued by MCA and SEBI, 60th AGM of the Company shall be conducted through VC/OAVM. Central Depository Services (India) Limited (CDSL) will be providing facility for remote e-voting, participation in the AGM through VC / OAVM and e-voting during the AGM.
- 5. As the AGM shall be conducted through VC/ OAVM, the facility for appointment of Proxy by the Members is not available and hence, Proxy Form, Attendance Slip and Route Map are not annexed to this Notice.
- 6. Shareholders attending the AGM through VC/OAVM shall be reckoned for the purpose of quorum for the AGM as per Section 103 of the Companies Act, 2013 (Act)